Rare Primary Central Nervous System Tumors in Adults: An Overview by Franceschi, C. (Claudio) et al.
REVIEW
published: 26 June 2020
doi: 10.3389/fonc.2020.00996
Frontiers in Oncology | www.frontiersin.org 1 June 2020 | Volume 10 | Article 996
Edited by:
André O. von Bueren,
Hôpitaux Universitaires de Genève,
Switzerland
Reviewed by:
Carsten Friedrich,
University of Rostock, Germany
Christian Hagel,
University Medical Center
Hamburg-Eppendorf, Germany
*Correspondence:
Enrico Franceschi
enricofra@yahoo.it
Ahmed Idbaih
ahmed.idbaih@aphp.fr
Specialty section:
This article was submitted to
Neuro-Oncology and Neurosurgical
Oncology,
a section of the journal
Frontiers in Oncology
Received: 24 February 2020
Accepted: 20 May 2020
Published: 26 June 2020
Citation:
Franceschi E, Frappaz D, Rudà R,
Hau P, Preusser M, Houillier C,
Lombardi G, Asioli S, Dehais C,
Bielle F, Di Nunno V, van den Bent M,
Brandes AA, Idbaih A and EURACAN
Domain 10 (2020) Rare Primary
Central Nervous System Tumors in
Adults: An Overview.
Front. Oncol. 10:996.
doi: 10.3389/fonc.2020.00996
Rare Primary Central Nervous
System Tumors in Adults: An
Overview
Enrico Franceschi 1*, Didier Frappaz 2, Roberta Rudà 3, Peter Hau 4, Matthias Preusser 5,
Caroline Houillier 6, Giuseppe Lombardi 7, Sofia Asioli 8, Caroline Dehais 9, Franck Bielle 10,
Vincenzo Di Nunno 1, Martin van den Bent 11, Alba A. Brandes 1, Ahmed Idbaih 9* and
EURACAN Domain 10
1Department of Medical Oncology, Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy, 2Department of
Neuro-Oncology and Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France, 3Department of
Neuro-Oncology, City of Health and Science and University of Turin, Turin, Italy, 4Wilhelm Sander NeuroOncology-Unit,
Department of Neurology, University Hospital Regensburg, Regensburg, Germany, 5Division of Oncology, Department of
Medicine I, Medical University of Vienna, Vienna, Austria, 6 Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin,
Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 7Department of Oncology, Veneto Institute of Oncology-IRCCS, Padua,
Italy, 8 Section of Anatomic Pathology “M. Malpighi”, Department of Biomedical and Neuromotor Sciences, Bellaria Hospital,
Bologna, Italy, 9 Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP,
Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France, 10Department of
Neuropathology, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, SIRIC Curamus,
Paris, France, 11 The Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, Netherlands
Overall, tumors of primary central nervous system (CNS) are quite common in adults
with an incidence rate close to 30 new cases/100,000 inhabitants per year. Significant
clinical and biological advances have been accomplished in the most common adult
primary CNS tumors (i.e., diffuse gliomas). However, most CNS tumor subtypes are
rare with an incidence rate below the threshold defining rare disease of 6.0 new
cases/100,000 inhabitants per year. Close to 150 entities of primary CNS tumors
have now been identified by the novel integrated histomolecular classification published
by the World Health Organization (WHO) and its updates by the c-IMPACT NOW
consortium (the Consortium to InformMolecular and Practical Approaches to CNS Tumor
Taxonomy). While these entities can be better classified into smaller groups either by their
histomolecular features and/or by their location, assessing their treatment by clinical trials
and improving the survival of patients remain challenging. Despite these tumors are rare,
research, and advances remain slower compared to diffuse gliomas for instance. In some
cases (i.e., ependymoma, medulloblastoma) the understanding is high because single or
few driver mutations have been defined. The European Union has launched European
Reference Networks (ERNs) dedicated to support advances on the clinical side of rare
diseases including rare cancers. The ERN for rare solid adult tumors is termed EURACAN.
Within EURACAN, Domain 10 brings together the European patient advocacy groups
(ePAGs) and physicians dedicated to improving outcomes in rare primary CNS tumors
and also aims at supporting research, care and teaching in the field. In this review,
we discuss the relevant biological and clinical characteristics, clinical management of
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patients, and research directions for the following types of rare primary CNS tumors:
medulloblastoma, pineal region tumors, glioneuronal and rare glial tumors, ependymal
tumors, grade III meningioma and mesenchymal tumors, primary central nervous system
lymphoma, germ cell tumors, spinal cord tumors and rare pituitary tumors.
Keywords: pineal tumors, mesenchymal non meningothelial intracranial tumors, CNS lymphoma, germ cell
tumors, pituitary tumor, glioneural tumor, embryonal tumor of central nervous system, medullobalstoma
INTRODUCTION
The European Union has launched 24 European Reference
Networks (ERNs). ERNs are virtual networks involving
healthcare providers across Europe aimed to tackle complex
or rare diseases that require highly specialized approaches and
concentrated knowledge and resources. The ERNs include a
network for rare adult solid cancers called EURACAN.
Taken in totality as one group of cancer, primary central
nervous system (CNS) tumors are quite common with an
incidence rate close to 30 new cases/100000 inhabitants per
year, in adults. Nevertheless, more than 150 entities—many
of which are rare or ultrarare—have now been categorized
by the World Health Organization and by the c-IMPACT
NOW consortium (1). Each of them has an incidence rate
below 6.0 new cases per year/100,000 inhabitants (which is
the threshold definition for rare diseases). The most common
adult primary CNS tumors are diffuse gliomas and grade I and
II meningiomas.
Many other entities grouped either by ontogenesis,
by histomolecular features or by CNS location are less
common. These include medulloblastoma and embryonal
tumors, pineal region tumors, glioneuronal and rare
glial tumors, ependymal tumors, grade III meningioma
and mesenchymal tumors, primary CNS lymphoma and
hematological diseases, germ cell tumors, spinal cord tumors,
rare pituitary tumors and ultrarare tumors. Due to their rarity,
progress in biological and clinical research is in most of the
cases slow.
Within EURACAN, Domain 10 (the ERN for adult rare
primary CNS tumors) brings together the European patient
advocacy groups (ePAGs), physicians and researchers from
EU countries, who are highly specialized in the field of
rare primary CNS tumors and who support research, care
and teaching in the field. EURACAN is therefore working
in close collaboration with European neuro-oncology groups,
particularly: (i) the Brain Tumor Group of the European
Organization for Research and Treatment of Cancer (EORTC
BTG), (ii) the European Association of Neuro-Oncology
(EANO), (iii) national neuro-oncology working groups and, (iv)
and with ePAGs in particular the International Brain Tumor
Alliance (IBTA).
EURACAN Domain 10 is structured in multiple subdomains
to cover all subgroups of rare adult primary CNS tumors.
Medical and biological advances to date are summarized in the
current review.
MEDULLOBLASTOMA AND EMBRYONAL
TUMORS
Medulloblastoma
Medulloblastoma is an embryonal tumor originating from
cerebellum, is rare in post-pubescence and adulthood with an
estimated incidence of 0.05–0.1 patients per 100,000 per year
(2–9).
Medulloblastoma biology varies between different age groups,
resulting in distinct tumor subtypes with distinct clinical
behavior. The diagnostic and therapeutic pathways suggested for
adult and post-pubertal patients in a recent European consensus
paper are based largely on extrapolations of pediatric data (3).
The heterogeneity of medulloblastoma gives rise to a range
of subtypes. The revised 2016 WHO classification provides a
definition of medulloblastoma according to both histologic and
genetic features (1). Four distinct subgroups can be distinguished
at the genetic level: (i) WNT activated; (ii) SHH activated
and TP53 wildtype; (iii) SHH activated and TP53 mutant; and
(iv) non-WNT/non-SHH.
SHH-activated TP53-wildtype medulloblastomas are the
most common in adults, representing about 60% of cases
(10). Mutations in either PTCH1 or SMO are present in
over 80% of this subgroup in adults and represent excellent
candidates for molecularly targeted therapy (11). While rare
in adult SHH-driven medulloblastomas, the TP53 mutation
confers a worse prognosis (12). Adults with WNT-driven
medulloblastoma constitute about 15%, and non-WNT/non-
SHH medulloblastomas around 25% of cases (10).
The classical Chang staging system considers the size and
amount of tumor infiltration (T1–T4) and divided metastatic
stage into M0 to M4 (13). However, prognostic factors identified
in trials with pediatric patients have not been unequivocally
confirmed in adults. In contrast to the situation in children, the
prognostic role of M stage and post-resection residual tumor
>1.5 cm2 (9, 14) have not yet been convincingly validated.
Outcomes of the different medulloblastoma subgroups vary
depending on age (10, 15). Large cell/anaplastic histology is a
high-risk feature in adults (16).Whereas, adults with SHH-driven
medulloblastoma have more favorable overall survival (OS)
than non-WNT/non-SHH tumors (16, 17), adults with WNT-
driven medulloblastoma do not show the favorable outcomes of
pediatric patients (17, 18). The TP53mutation is associated with
a poor prognosis (12, 16), while MYCN amplification confers a
worse prognosis in the SHH subtype (16), it does not in group 4
tumors (18).
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Medulloblastoma affords a curative treatment approach and
thus involves intensive treatments that bear the risk of clinically
relevant side effects. Gross total resection (GTR) should be
performed in all patients to alleviate symptoms and facilitate
diagnosis (4). The backbone of post-operative treatment with
adjuvant chemoradiation comprises craniospinal irradiation
(CSI) to a total dose of 36 or 35.2Gy and local dose escalation to
the posterior fossa (to a total dose up to 54–55.8Gy) (5). Lower
doses for CSI of 23.4Gy or even 16Gy have been systematically
investigated in children, but not in adults, with comparable
efficacy (19). Inmany centers worldwide, lower CSI doses are also
used in adults. If available, proton therapy can be considered as an
alternative to helical IMRT (Intensity-Modulated RadioTherapy)
or VMAT (Volumetric Modulated Arc Therapy) for reduction of
long-term side effects (20, 21). Similar survival outcomes were
reached in children with protons compared to photon irradiation
(22). Recommendations about systemic treatments are mainly
provided by the results of pediatric trials, retrospective series
of adult cohorts within pediatric trials with only single single-
arm prospective trial in adults (6–9). It must be realized that
the tolerance for chemotherapy is less in adults as compared
to children.
Medulloblastomas are comparably well-understood and thus
amenable to risk stratification and targeted therapies (11,
17). Stratification of patients into prognostic and therapeutic
subgroups is a prerequisite to individualized treatment, e.g., to
identify patients who may benefit from IMRT-chemotherapy or
targeted treatment. However, prospectively validated predictors
are scarce in post-pubertal and adult patients. The first
genotype-based trial in adults (EORTC 1634-BTG) will start
in 2020.
Due to the CNS location of medulloblastomas, late toxicity
is a key issue (23). In an effort to reduce toxicity, standard
CSI to a total dose of 36 or 35.2Gy (five times weekly) can
likely be reduced to 23.4Gy without loss of efficacy if combined
with chemotherapy (24) and dose escalation to the tumor
bed >50Gy (25). Packer chemotherapy is less well-tolerated
by adults than children (6, 7, 26). Moreover, lower doses of
the chemotherapeutic agent cisplatin do not seem to result in
decreased efficacy, and strict stopping rules in cases of ototoxicity
thus seem justified (27), at least in children. Substitution of
cisplatin for carboplatin has not been systematically investigated
in adults.
Although the data are currently limited to individual objective
responses in small cohorts (28, 29) the most promising and
mature targeted approach is to use the SMO inhibitors sonidegib
or vismodegib in SHH-driven medulloblastoma, preferably
within clinical trials. Response to SMO inhibitors can be
predicted by high-throughput genomic methods (30). It however
remains unclear whether the SHH signaling pathway should be
investigated for downstream mutations before initiating SMO
inhibition, as adults tend to have mutations at the level of
SMO or above, which do not confer primary resistance to
these targeted agents (30). Patients with an initial response to
SMO inhibition typically relapse in the subsequent course (31).
Resistance to SMO inhibitors may be overcome by novel agents
(32). As the spectrum of druggable targets may change in relapse
(33), recurrent tumors should be re-biopsied before initiating
SMO inhibition.
Systemic treatments such as MEMMAT (metronomic
and angiogenesis inhibition, NCT01356290) (34), TOTEM
(topotecan and temozolomide, NCT00918320) (35), or TEMIRI
(temozolomide, irinotecan) (36) [some of these approaches
supplemented with bevacizumab (24, 37) and/or temozolomide
(35–37)], are not specific for particular subpopulations, although
their rationale is also found in a systems-biology and therefore
pathophysiology-based approach.
The increasing complexity of medulloblastoma classification
(38, 39) makes it likely that novel druggable targets will soon be
available. For example, among the newly described non-WNT-
and non-SHH-driven medulloblastoma subgroups (39), ∼40%
of patients harboring MYC amplifications may be candidates
for immune checkpoint inhibition. It is probable that patients
will be clustered in increasingly small subgroups in the future,
thus generating a high demand for high-throughput diagnostic
methods and also raising the question of financial reimbursement
within the healthcare systems. Other recent clinical trials enroll
small, highly selected populations, i.e., for immune checkpoint
inhibition studies (NCT03838042, NCT03130959).
Liquid biopsies of CSF, serum, and urine that contain tumor
cells, circulating cell-free DNA, extracellular vesicles, or proteins
are currently being investigated and may provide a less invasive
tool for early detection of tumor load, recurrence, and druggable
targets (40), as demonstrated for other entities (41).
PINEAL REGION TUMORS (PRTs)
Incidental diagnosis of pineal region masses occurs in about 1–
10% while diagnosis during autopsy of pineal masses occurs in
20–40% of cases (42). Nonetheless, the majority of these masses
are benign and asymptomatic requiring observation as only
approach. Pineal tumors are rare, representing 0.5 to 1% of adult
CNS tumors in Europe and the United States, and 4% in Japan.
They belong to five different histological entities: (i) tumors of the
pineal parenchyma (representing 25–30% of all cases), (ii) germ
cell tumors -GCT-, (iii) glial tumors and, (iv) metastatic location
of systemic cancer and (v) papillary tumor of the pineal region.
PRTsmost oftenmanifest initially as non-specific neurological
signs related to tumor site. Symptoms related to their growth
are: hydrocephalus (due to aqueduct of Sylvius obstruction),
Parinaud syndrome (compression of superior colliculi) or
endocrine disturbances. Once that pineal origin of tumor is
confirmed an adequate staging through review of CNS imaging
should be done in parallel with a complete physical and clinical
examination. GCT is the most probably diagnosis if a second
location is observed in supra-optic region while detection of
second location elsewhere suggest lymphoma or metastasis
as alternative diagnosis. Some malignancies like atypical-
teratoid/rhabdoid tumor (AT/RT), CNS embryonal tumors,
pinealoblastoma, or lymphoma should be suspected when there
is a meningeal enhancement.
To achieve a complete staging a spinal MRI (if possible before
surgery), CSF cytology (during surgical shunting or by lumbar
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puncture) should be performed. Evaluation of markers (AFP,
total and free HCG chain) in serum and CSF is also important
to avoid unnecessary primary surgery.
Ophthalmologic examination will focus on visual acuity and
field and rule out a lymphomatous pseudouveitis diagnosis.
Endocrinological investigations are needed to rule out diabetes
insipidus, or a sexual and/or growth hormones deficiency even if
no supraoptic mass is detectable.When hydrocephalus is present,
urgent shunting should be discussed.
Then, a multidisciplinary medical neuro-oncology board
should discuss the necessity and the technical tools to obtain
pathological proof if required, according to age, race and lesion
staging. PRT may occur at any age.
Among adolescent and young adults, CGT represents the
most common diagnosis. However, gliomas and tumor of the
pineal gland including pinealocytoma or pinealoblastoma should
be suspected. Gliomas, lymphomas, and metastases are more
frequent in adults. Pineal cysts should be discarded whatever
the age.
GCT are more frequent in Asians (43, 44). Chemotherapy
as primary approach should be performed in patients with
positive markers (blood and/or CSF), lymphomatous cells in CSF
and/or specific alterations of slit lamp. Nonetheless, pathological
specimens and diagnosis should be obtained through surgical
resection or biopsy performed as open biopsy or during
ventriculocisternotomy. Neurosurgeons expert in this region of
the brain should perform surgery.
The treatment will then be tailored according to each
pathology. The WHO 2016 classification proposes a three-stage
classification (grade I, II or III, and IV) of tumors of the
pineal parenchyma. The MIB1 proliferation index is increasing
between grade I to IV (45). DNAmethylation profiling of tumors
of the pineal region confirms these three distinct subgroups:
pinealocytoma, pinealoblastomas and pineal parenchymal tumor
of intermediate differentiation (PPTID) (46).
Pinealocytoma
Pinealocytoma is the most differentiated tumor type. It shows no
mitosis or necrosis. Neuronal and/or neuroendocrine markers
are present (neurofilaments, synaptophysin, chromogranin A)
with sometimes S antigen and rhodopsin resembling the pineal
phylogenesis. It lacks genomic copy number abnormalities. It
occurs mostly in adults above 40 years old. Treatment includes
complete surgery when feasible, with no further treatment.
Pinealoblastoma
Pinealoblastoma is the most aggressive tumor (grade IV),
and is defined as an embryonal undifferentiated tumor, with
monomorphous small blue round cells that mimic those of any
other CNS embryonal tumors, particularly medulloblastoma. It
may show neuroblastoma-like Homer-Wright pseudorosettes or
retinoblastoma-like Flexner Wintersteiner rosettes. It expresses
INI1 that allows ruling out AT/RT. DNA copy number
profiling suggests a close relationship between CNS-embryonal
tumors and pinealoblastoma (47). Recurrent variants are found
in genes involved in PKA- and NF-κB signaling pathways,
and chromatin remodeling machinery (48). Mutually exclusive
DICER1 mutation, DROSHA homozygous deletion and absence
of KBTBD4 distinguish pinealoblastoma (49). Two peaks of
incidence could be observed in pinealoblastoma incidence: the
first in the two first decades of life and the second before
10 years old. Methylation profiles differ between pediatric
and adult pinealoblastoma suggesting that pediatric tumors
arise de novo while adult pinealoblastoma may arise from a
pineal parenchymal tumor or a normal pineal gland. DNA
methylation profiling reveals three subtypes and two new
subgroups that are exclusively present before 7 year of age:
(i) Pinealoblastoma-RB displays similarities with retinoblastoma
and, (ii) Pinealoblastoma-MYC when MYC activation is present.
Alterations within the miRNA processing pathway (affecting
DROSHA, DGCR8, or DICER1) are found in about two thirds
of cases in the three core subtypes (46). Treatment strategies
mimic those for other malignant embryonal brain tumors.
Significant treatment experience has been gained in pediatrics
(50). After maximal resection, an application of chemotherapy
(often platinum based) with radiation (usually CSI with local
boost) is proposed. Using this strategy in 10 adults, a 3-year PFS
of 68% was reported (51). Out of 45 patients aged 18 years or
above, with malignant pineal tumors treated with radiotherapy
followed by chemotherapy (in 34/45 patients), the median OS
was 100 months. The extent of initial disease, differentiation
(PPTID vs. pinealoblastoma), and residual disease significantly
influenced OS as independent factors in a multivariate analysis.
Local control was better in patients older than 32 years. Spinal
control was increased in PPTID. Treatment failures occurred
more than 5 years after treatment in 20% of cases. The median
survival after relapse was 15 months. (51). Out of 135 patients
with pinealoblastoma aged 0.01 to 20.7 years (median 4.9),
favorable prognostic factors for progression free survival (PFS)
were age, administration of radiotherapy and M0 staging (52).
Pineal Tumor of Intermediate
Differentiation (PPTID)
PPTIDs are tumors that fall between pinealocytoma and
pinealoblastoma. They are composed of round cells with
abundant cytoplasm and “poivre et sel” chromatin. Some
necrosis or endothelial proliferation may exist. There are no
consensual grading criteria between grade II and III according to
WHO classification. Pinealoblastomas and PPTIDs share similar
structural and numerical abnormalities including alterations of
chromosome 1 and loss of chromosomes 20 and 22. TheKBTBD4
small in-frame insertion as well as the absence of DROSHA
deletion or DICER1 mutation characterized PPTID (49). They
occur in people between 20 and 40 years. Due to their rarity
management of these tumors still remains not clearly defined.
Surgery with complete removal is the best treatment option. Local
or CSI is usually recommended in grade III tumors.
Other pineal tumor types may also be diagnosed, such as GCT
(discussed in further chapter), glial tumors and metastases from
other tumor types.
Glial Tumors of the Pineal Region
Glial tumors include pilocytic astrocytomas, high-grade gliomas,
ependymomas and papillary tumors of the pineal gland (PTPG).
Frontiers in Oncology | www.frontiersin.org 4 June 2020 | Volume 10 | Article 996
Franceschi et al. Rare Central Nervous System Tumors
Low-grade gliomas may be also observed. They may be
difficult to diagnose on tiny biopsies and may be confused with
piloïd gliosis of a pineal cyst or of gliosis surrounding another
tumor type. The presence of a KIAA1549:BRAF fusion transcript
or its variants is of major diagnostic value. Gangliogliomas were
also reported in this location (53). The treatment does not differ
from that of low-grade gliomas located elsewhere. Glioblastomas
are very rare. They display features of diffuse midline and non-
midline gliomas. Median age at diagnosis is 50 years. Only one
case showed the histone H3 K27M-mutation while no evidence
of IDH-1 R132H mutation or 1p/19q co-deletion are available.
Nonsense mutations in ATRX and NF1 could be showed by
targeting exome sequencing. Despite adjuvant radiation and
chemotherapy, median OS is 15 months (54). Case reports of
pineal gliosarcoma have been published (55).
Papillary Tumors of the Pineal Region
(PTPR)
PTPRs are very rare neuroepithelial tumors issued from the
subcommissural organ. They are characterized by an epithelial-
like, loose papillary growth pattern, expression cytokeratins, and
less often EMA and GFAP. Genome wide profiling identify loss of
chromosome 10 in all and other chromosome imbalances. PTEN
mutations are seen, with activation of the PI3K/Akt/mTOR
signaling pathway (56). PTPRs overexpress SPDEF, a rodent
subcommissural organ gene. DNA methylation profiling reliably
distinguished PTPR from ependymomas and PPTID. Two
groups with clinical relevance were proposed (57). They affect
children and adults (mean age at diagnosis 35 years). A
recent cohort of the 177 cases published so far, showed that
56% recurred after a median 29 months with a 36-months
survival rate of 83%. After adjustment for age, tumor size and
surgical treatment were associated with survival. However, no
significant benefits from GTR or adjuvant treatments including
radiotherapy were reported (58).
GLIONEURONAL TUMORS AND RARE
GLIAL TUMORS
Pilocytic Astrocytoma
Pilocytic astrocytomas (PAs) represent 5.4% of gliomas and
are most common during the first two decades of life and in
young adults. They are the principal CNS neoplasms associated
with neurofibromatosis type 1, particularly those involving the
optic pathways. In adults, the onset is earlier as compared to
diffuse astrocytomas. The definition by WHO 2016 is that of
an astrocytoma with a biphasic pattern composed of a variable
percentage of compacted bipolar cells with Rosenthal fibers and
loose, textured multipolar cells with microcysts and occasional
granular bodies. The tumor is WHO grade I, but cases with
anaplasia may occur. IDH 1-2 mutations are absent, while
specific fusions are present fusing BRAF with KIAA1549 or
other partners.
Preferred locations are optic nerve/chiasm,
hypothalamus/thalamus, cerebellum, brain stem, cervico-
medullary junction and cerebral hemispheres with focal
neurological deficit, endocrinopathy and raised intracranial
pressure as the most frequent symptoms at onset. On MRI,
PAs classically appear as cystic masses with an enhancing
mural nodule.
The standard of care consists of a GTR for accessible
lesions (i.e., cerebellum, cerebral hemispheres) with a 10-year
survival rate of 100% as compared to 74% for subtotal resection
(59). Resection is more problematic in critical locations, such
as optic pathways, thalamus, and hypothalamus. Exophytic
portions of tumors in brainstem and cervico-medullary
junction are resectable. Adjuvant radiotherapy for incomplete
resection/biopsy prolongs PFS but equivalent OS are reported
with observation and salvage radiotherapy. IMRT and proton
facilities may be useful to minimize damage to surrounding
normal structures. Chemotherapy is used to avoid/delay
radiotherapy in children or as salvage treatment (carboplatin +
vincristine, temozolomide, multidrug combinations) in adults.
BRAF inhibitors have been proposed for patients with BRAF
V600E mutation.
Pleomorphic Xanthoastrocytomas
Pleomorphic xanthoastrocytomas (PXAs) represent <1%
of astrocytic neoplasms, sometimes associated with
neurofibromatosis type 1. The definition of WHO 2016 is
that of an astrocytic glioma with large pleomorphic and
frequently multinucleated cells, spindle and lipidized cells, a
dense pericellular reticulin network, numerous eosinophilic
granular bodies, and often a neuronal differentiation. It is a grade
II tumor, but in up to 30% of cases, anaplastic features (WHO
grade III) are present. IDH 1-2 mutations are absent; MGMT
promoter methylation is rare, while BRAF V600E mutation
is observed in 50–70% of cases. MRI shows a supratentorial
lesion, more often in the temporal lobe, involving the cortex and
overlying leptomeninges, frequently cystic, with moderate or
strong contrast enhancement.
As for management (60), GTR, when feasible, is the standard
of care but frequently a local progression occurs. Eighty
percent of patients undergo reoperation alone or followed by
radiotherapy, while 20% of patients receive radiotherapy alone.
In 30% of patients, chemotherapy (temozolomide, bevacizumab,
CCNU, lapatinib), is also used. There are increasing reports of the
efficacy of BRAF inhibitors (vemurafenib, dabrafenib), alone or
associated with MEK inhibitors (cobimetinib, trametinib) (61).
Subependymal Giant Cell Astrocytomas
Subepedymal giant cell astrocytomas (SEGAs) occur in patients
with tuberous sclerosis complex (TSC). The TSC is an
autosomal—dominant genetic disease characterized by gene
mutation of hamartin (TSC1) or tuberin (TSC2). These proteins
are generally involved in inhibition and suppression of mTOR
pathway, which is known to be involved in cell proliferation.
Children are mostly affected.
SEGAs are WHO grade I lesions localized most commonly in
the region of the foramen of Monro. These lesions arise from
subependymal nodules covering ventricles.
The most common symptoms are pharmacoresistant seizures,
while MRI shows a homogeneous enhancing lesion.
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Surgery represents the best treatment option for lesions
associated to increasing growth or symptomatic lesion presenting
for example with obstructive hydrocephalus.
Due to the location, morbidity following surgical resection is
observed in 20–50% of patients. In the last 10 years everolimus,
an m-TOR inhibitor, is being increasingly used also as first-
line treatment, due to a clear activity on tumors and seizures.
In a phase III trial patients were randomized to receive
everolimus or placebo. Of note, patients receiving everolimus had
a radiographic response rate of 35% compared to 0% in patients
receiving placebo (62). In addition, seizures are reduced in up to
70% of patients. Responses to everolimus last for several years,
and overall, the outcome of SEGAs is favorable but the patients
are mentally retarded and suffer from seizures.
Gangliogliomas
Gangliogliomas (GGs) are rare tumors accounting for 0.5–
1.3% of all primary CNS tumors and are more frequent in
children than in young adults. They are composed of dysplastic
ganglion cells in association with neoplastic glial cells. Neuronal
component is recognized by antibodies to neuronal proteins
(neurofilaments, synaptophysin, chromogranin A), while the
glial component is immunostained for glial fibrillary acid protein
(GFAP). IDH 1/2 mutations and 1p/19q codeletion are absent,
H3K27Mmutation can be found in midline tumors, while BRAF
V600E mutation is observed in 20–60% of cases (63). BRAF
V600E mutation is associated with mTOR pathway activation in
dysplastic neurons. The prognostic role of molecular alterations
is unclear. Anaplastic GGs correspond histologically to WHO
grade III and the frequency varies from 1 to 6%.
On MRI, lesions are cortically-based and well-circumscribed,
either solid or cystic with a mural nodule, and calcifications
are present in ∼50% of patients. Contrast enhancement may be
absent or present in variable degree.
Surgical resection is the main therapeutic option, and GTR
is often feasible in the hemispheric locations, and is the best
predictor of prolonged PFS and OS. Seizure freedom following
GTR is obtained in 70–90% of patients. Early surgical resection,
shorter duration of epilepsy (≤1 year), younger age and absence
of secondary generalized seizures are associated with better
seizure control (64). Grade I GG patients have an OS of 84–
94% at 10 and 15 years. Malignant transformation of GGs varies
from 2 to 5%. Conformal radiotherapy can be used as adjuvant
treatment in incompletely resected GGs but it is unclear whether
it is better than surveillance postponing RT at progression.
Rarely, recurrent tumors respond to nitrosoureas, temozolomide,
etoposide, or platinum compounds. Responses to BRAF-mutated
tumors to BRAF inhibitors, alone or with MEK inhibitors, have
been reported suggesting that these drugs can be an important
treatment option (61).
EPENDYMAL TUMORS
Ependymomas constitute 8–10% of brain tumors in children and
1–3% of primary brain tumors in adults (65). The small number
of patients included in the studies, the heterogeneity in terms of
age and location as well as the long time period analyzed explain
the lack of evidence-based treatment strategies. Overall, adults
have a better prognosis than children with 5-year survival rates
of 56–85%compared to 36–64%, respectively.
In adults, ependymomas definitely prevail in the spinal cord
(the cervical and thoracic locations are more common), while
in children they prevail in the posterior fossa (60%), and are
typically located in the fourth ventricle or in the cerebello-
pontine angle. Ependymomas in the supratentorial compartment
are more frequent in adults (50–60%) as compared to children
(30%), and are located in the lateral or 3rd ventricles (60%)
or in the brain parenchyma (40%). They are more often high-
grade tumors.
According to WHO 2016, diagnosis of anaplastic
ependymoma can be done in ependymal tumors with associated
high mitotic rate, high cell density, necrosis, and widespread
microvascular proliferation. Histopathological grading has
been for many years a matter of discussion; however, as several
recent studies (66) have demonstrated a different outcome for
ependymomas grade II and grade III, this distinction is still used
for clinical decision.
Recently, molecular profiling has identified nine subtypes
of ependymomas (the subtypes in each location) with different
outcomes (67). In particular, the variant RELA fusion
(supratentorial location and poor outcome) has been added
in the updated WHO 2016 classification.
Intracranial Ependymomas
About pattern of failure, incidence of CSF dissemination at
time of diagnosis is <5% but increase to 15% in patients with
anaplastic and infratentorial tumors. It is also important to
observe that majority of tumor recurrences (up to 90–95%)
happens due to the lack of local tumor control, while the
occurrence of extraneural metastases is extremely rare (<1%).
After surgery, a craniospinal MRI and an assessment
of CSF cytology are mandatory (not earlier than 2 weeks
after surgery, to avoid confusion with peri-operative tumor
spill). Regular surveillance with MRI of the entire CNS
could discover asymptomatic recurrences (43%) and impact
subsequent treatment and survival (68). Open questions are how
often and for how long the surveillance should be performed and
when CSF cytology is needed.
Surgery is the mainstay in the management of ependymomas
(69). Gross total resection (GTR) is the most important
prognostic factor for patients with localized disease, and image-
verified (MRI) gross total resection is achieved in 50–75% of
patients. GTR is dependent upon tumor location and infiltration.
The definition of GTR is crucial in order to define risk
classification and guide treatment decisions. Second-look surgery
following initial incomplete surgery is increasingly advocated
(especially in children), assuming that a complete resection is
achievable. GTR cannot be performed at primary surgery due to:
(1) patients in extremis immediately prior to surgery; (2)
findings during operation different from predicted at imaging; (3)
neurosurgeon experience.
Open issues are when the second surgery is to be performed
(as soon as possible? After a period of observation?). A second
surgery is recommended whenever feasible at recurrence.
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Conformal radiotherapy is part of the standard of care
as adjuvant treatment for patients with anaplastic (grade III)
ependymoma and for patients with grade II ependymoma after
incomplete resection. Doses of 54–55Gy for grade II tumors
and 60Gy for grade III tumors are commonly used. There is
no evidence of efficacy for radiotherapy after GTR of a grade II
tumor (70).
CSI was the SCI for many years, based on the propensity of
ependymomas to spread via the CSF, but recent studies report no
differences in outcome (including the rate of spinal metastases)
when larger treatment volumes have been used. Nowadays,
limited field radiotherapy is used for localized tumors (MO) and
CSI is restricted for patients with metastatic disease (M1) (69).
Reirradiation at recurrence can be performed using a full course
either of fractionated irradiation or stereotactic irradiation or, in
some specialized centers with proton therapy.
Durable responses following reirradiations can be achieved.
In addition, durable survival has been observed with resections
of localized metastases, being salvage surgery another option.
Chemotherapy, especially in adults, is used especially at
recurrence with drugs such as platinum compounds (71) or
temozolomide (72).
Spinal Cord Ependymomas
The two histologic subtypes are represented by myxopapillary
ependymoma (grade I) arising in the cauda equina and classic
ependymoma (grade II or III) arising more often in the cervical
spinal cord (65, 73).
The risk of CSF spread in classic ependymoma is rare. Grade
I myxopapillary ependymoma could have a worse prognosis than
grade II tumors, due to a lower frequency of total resections and
increased risk of mechanical CSF disseminations. Re-operation
should be performed whenever feasible.
Post-operative conformal radiotherapy prolongs PFS in
incompletely resected tumors. A risk of radiation-induced
myelopathy should be considered. Reirradiation, also with
stereotactic techniques, can be useful for local recurrence.
Chronic oral etoposide for patients relapsing despite surgery and
radiotherapy has been reported with some efficacy.
GRADE III MENINGIOMA AND
MESENCHYMAL NON MENINGOTHELIAL
INTRACRANIAL TUMORS
Grade III Meningiomas
Anaplastic meningiomas account for ∼1–3% of meningiomas
and exhibit malignant cytology (resembling that of carcinoma,
melanoma, or high-grade sarcoma) and/or markedly elevated
mitotic activity (1). In addition to high mitotic activity many
anaplastic meningiomas show extensive necrosis and Ki-67
tumor cell proliferation indices of 20% or higher. According
to the WHO classification of tumors of the CNS, anaplastic
meningiomas correspond to grade III. The rare histological
rhabdoid and papillary meningioma variants also correspond to
grade III. They have high recurrence rates and may metastasize
to extracranial sites. The prognosis of anaplastic meningiomas is
poor with median OS below 1 year.
Molecularly, anaplastic meningiomas show high rates of
NF2 aberrations. Hotspot mutations in the TERT promoter
were found in 20% of WHO grade III meningiomas (1.7 and
5.7% in WHO grade I and II meningiomas, respectively) and
are associated with unfavorable outcome (74). In rhabdoid
meningiomas, germline, and somatic mutations of BAP1 gene
have been identified and may be linked to unfavorable outcomes
(75). Epigenetic signatures have been shown to correlate with
clinico-pathological features in meningiomas and anaplastic
meningiomas were associated with the unfavorable specific
methylation profiles (MC-mal and MC-int B) (76).
Therapeutic strategy for anaplastic meningiomas at initial
diagnosis should aim at radical resection followed by fractionated
radiotherapy at a dose of at least 54 to 60Gy delivered in 1.8–
2.0Gy fractions (potentially with a 10Gy boost on the remaining
tumor volume after subtotal resection) (77). No evidence-
based treatment recommendations for recurrent anaplastic
meningioma exist, but usually resection or radiotherapy is
recommended, if possible. Pharmacotherapy of anaplastic
meningiomas remains experimental and no efficacy for specific
drugs has been proven.
Solitary Fibrous
Tumor/Haemangiopericytoma
Incidence of the Solitary fibrous tumor/haemangiopericytoma is
<1% of all primary CNS tumors. It occurs most commonly in
adults and is typically dura-based. Histologically, solitary fibrous
tumor/haemangiopericytoma appears as a mesenchymal tumor
with fibroblastic pattern. Genomic inversion at the 4 12q13 locus
resulting in the NAB2 and STAT6 genes fusion can be frequently
observed. Detection of nuclear STAT6 expression or detection
of NAB2-STAT6 fusion is highly recommended to confirm
the diagnosis of solitary fibrous tumor/haemangiopericytoma
(78–81). Two main phenotypes are described: the classic
solitary fibrous tumor phenotype is characterized by pattern-
less histomorphology, rich collagen matrix and scarce mitoses.
In contrast, the haemangiopericytoma phenotype shows high
cellularity and increases mitotic activity and necrosis (1).
These two phenotypes belong to a same tumor spectrum
of intermediate malignancy with a risk of local relapse and
metastasis increasing with higher mitotic activity and necrosis.
Drug treatment of solitary fibrous tumor/haemangiopericytoma
is experimental, as no effective agents have been identified. The
antiangiogenic multi tyrosine kinase inhibitor axitinib showed
some promising activity in a small uncontrolled phase II study
enrolling advanced or progressive solitary fibrous tumors and
should be validated in further studies (81, 82).
PRIMARY CNS LYMPHOMA
Primary cerebral lymphoma (PCL) is a rare form of non-
Hodgkin lymphoma representing <5% of primary cerebral
tumors (83). It may be associated with lymphomatous locations
in the meninges (15–20%), the eye (10–20%) and the spinal cord
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(<5%) but is defined by the absence of any systemic lesion.
Immunodeficiency, mainly in the setting of AIDS or organ
transplant, is the only well-recognized risk factor, but since the
improvement of antiretroviral therapy in AIDS, it mainly arises
in immunocompetent patients, with a median age of 65 to 70
years (84).
The clinical presentation is usually sub-acute and non-
specific, depending on the location of the disease in the
brain. On MRI, the disease typically presents as one or
several deep and periventricular expansive lesion(s) with
typical intense and usually rather homogeneous contrast
enhancement after gadolinium infusion (85), but there can
be atypical presentations, mimicking other brain tumors,
or without contrast enhancement. In immunocompromised
patients, contrast enhancement is most frequently peripheral
with necrosis in the center (86). Perfusion, diffusion and
spectroscopy sequences can be useful to direct toward the
diagnosis (87).
Inmost cases, the diagnosis is confirmed by a brain biopsy that
should be performed before the introduction of steroids which
can cause false-negative biopsies (vanishing lymphoma). In the
case of an associated meningeal or ocular involvement, the brain
biopsy can be avoided if the aspect of the lesion is typical on
MRI and if monoclonal lymphomatous cells are found on CSF
or vitreous analysis. All suspected patients should have a lumbar
puncture with cytological and flow cytometry analyses and an
ophthalmological examination with at least slit-lamp and fundus
examination before considering a brain biopsy. In more than
90% of cases, the pathological diagnosis is a diffuse large B-cell
lymphoma, mostly of ABC type (88). The tumor is usually EBV
positive in immunocompromised patients and EBV negative in
immunocompetent patients. The staging should also include a
full body CT scan and/or FDG-PET scan to exclude a systemic
location of the disease (89).
Treatments usually used in systemic lymphomas are not
efficient in PCL. The treatment of PCL consists of an intravenous
high-dose methotrexate (HD MTX) based polychemotherapy.
The use of rituximab is controversial (90). The tumor is
highly chemosensitive with 40–60% of complete response to
chemotherapy (91–94), but relapses are very frequent, notably
within the first months after the end of the treatment. In order
to reduce the risk of relapse, a consolidation treatment can be
delivered to patients with good response to initial chemotherapy,
with two options: whole-brain radiotherapy (WBRT) or high-
dose chemotherapy with autologous stem cells transplantation
(HCT-ASCT) (93–95). However, HD MTX combined with
whole-brain radiation therapy (WBRT) exposes patients to a
risk of delayed neurotoxicity (96). This risk is particularly
important in elderly patients who frequently develop dementia
and severe gait disorders after treatment so that WBRT has
been gradually abandoned in patients older than 60 years. HCT-
ASCT is restricted for patients under 60–65 years in good
clinical condition.
Age and Karnofsky performance status are the most well-
recognized prognostic factors, while the prognostic value of other
factors is controversial (CSF protein, blood LDH, early response
to chemotherapy or molecular factors such as chromosome 6q
loss for instance) (97, 98). The prognosis for the disease remains
severe, with a median OS of 30–60 months in most studies, but
the percentage of long-term survival has increased (5 year-OS of
38%) as showed in a recent population-based study (99).
GERM CELL TUMORS
Intracranial germ-cell tumors (GCT) derive from the primordial
germ cell: their aberrant migration occurs axially (i.e., suprasellar,
pineal regions with 10% being bifocal).
Pathology may include one (pure) or several (mixed) of the
following components that may not all appear in a limited
biopsy. Germinomas, the most frequent histology, are composed
of undifferentiated cells with some syncytiotrophoblastic cells
(explaining why germinomas may secrete ß-human chorionic
gonadotropin (HCG) intermixed with an inflammatory infiltrate.
Immunohistochemistry stains positive for placenta-like alkaline
phosphatase (PLAP). The other components may show aberrant
differentiation toward extraembryonic and/or somatic features:
yolk sac tumors stain for alpha fetoprotein (AFP) and
glypican 3; choriocarcinomas are composed of mononucleated
(cytotrophoblastic) and multinucleated (syncytiotrophoblastic)
cells that stain for HCG; and embryonal carcinomas stain for
CD30. Teratomas are either mature, with the presence of all three
germ layers, or immature, with varying components of immature
mostly neural tissue. Each component has its specific sensitivity
to treatment, germinomas being exquisitely sensitive, teratomas
resistant to radio-chemotherapy (indicating the need for surgical
removal), and other components being somewhere in-between.
There is a male predominance, especially for germinomas, a
racial predominance (Asiatic) and an age distribution: teratomas
and pure yolk sac tumors are mainly restricted to infants
and children whereas all others have a peak incidence during
adolescence and early adulthood and show isochromosome 12p
or 12p amplification.
In the pineal location, Parinaud’s syndrome and/or raised
intracranial pressure is recognized promptly. Suprasellar location
symptoms—diabetes insipidus, impairment of visual fields, or
variation in onset of puberty—are often overlooked for long
periods in adolescents. Basal ganglia germinomas occur in
Asiatic patients, as a longstanding history of focal deficit and/or
mental deterioration.
Pineal tumors may extend to the third and/or fourth ventricle
and invade the thalamic region. Suprasellar masses involve the
pituitary stalk and third ventricle and may compress or invade
the optic chiasm. Primary tumors tend to propagate along
the ventricular walls often causing endocrinological disorders
even when they are not radiologically detectable: disappearance
of the posterior pituitary bright spot correlates to diabetes
insipidus. Germinomas are iso- to hyperdense, sometimes
calcified on computer tomography scan, iso- or hypointense
on T1- and T2-weighted MRI, with moderate to marked
homogeneous gadolinium enhancement, a drop in apparent
diffusion coefficient values. The diffusion-weighted imaging
mimics that of Langerhans cell histiocytosis and lymphocytic
hypophysitis, but differs from craniopharyngiomas and gliomas.
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Bifocal tumors (if pineal and suprasellar) are a specific entity, not
a metastatic disease and are typical of GCT. Teratomas may be
suggested when the three compartments (parenchymal, fat, and
calcifications) are present. Basal ganglia germinoma MRI shows
atrophy of the cerebral peduncle, basal ganglia and/or cerebral
hemisphere. Spinal MRI, ideally performed preoperatively to
avoid bloody artifacts, should look for nodules and/or linear
enhancement. If doubtful, it should be repeated with both sagittal
and axial sequences.
Markers should be measured both in serum and CSF. Total
HCG is secreted by choriocarcinomas and at lower levels by
germinomas and embryonal carcinomas. Total HCG measures
both HCG and subunit β and is expressed as mUI/ml. Positive
cytology of CSF is found in 10% of cases.
The initial strategy requires a multidisciplinary approach.
The initial workflow is crucial and includes craniospinal MRI,
determination of markers (AFP and HCG) both in blood and
CSF, cytology of CSF. The incidence of relapses increased from
4 to 24% if incompletely staged germinomas. Apart from the
Japanese strategy (explained later), if markers (serum and/or
CSF) are positive, or for non-secreting bifocal tumors (most
likely germinomas) histological confirmation is not required.
Otherwise, open surgery, stereotactic biopsy, or endoscopic
third ventriculostomy may be used to obtain histological proof.
The latter is often used to relieve hydrocephalus and allows
inspection of the ventricles. Detection of ventricular nodules
during ventriculoscopy does not qualify the patient as metastatic,
if they are not detectable on MRI.
American and European groups define two-categories:
germinomas and non-germinomas. Localized germinomas were
initially treated within the SIOP (International Society of
Pediatric Oncology) GCT 96 protocol with either CSI of 24Gy
with a local boost of 16Gy, or combined treatment with
etoposide–carboplatin–ifosfamide (CarboPEI) followed by a 40-
Gy focal boost (100). Due to potential neurotoxicity in the
former regimen, and excess of ventricular relapses in the latter,
the current CGTII SIOP protocol explores the same induction
chemotherapy followed by whole ventricular irradiation (WVI)
of 24Gy with a 16-Gy boost, delivered exclusively in patients who
do not reach complete remission (CR) prior to radiation. The
Children’s Oncology Group (COG) launched ACNS 1123 that
explores combined treatment by etoposide–carboplatin, followed
by 18Gy of WVI with a 12-Gy boost in patients reaching CR, or
24Gy and 12Gy respectively otherwise (101).
Localized non-germinomas were treated in the two successive
SIOP trials with ifosfamide–etoposide–cisplatin (PEI) followed
by a 54-Gy boost to the primary. As SIOP-GCT96 cohort
reported a poorer prognosis for patients with AFP>1,000 and/or
with persisting viable tumor after chemotherapy (102), SIOP-
GCTII explores the role of high-dose therapy followed by stem-
cell rescue, prior to radiation, in these high-risk patients. ACNS
0122 delivered etoposide–carboplatin–ifosfamide with 36Gy of
CSI and a 18-Gy boost for patients in CR, and consolidation
by high-dose etoposide thiotepa with stem-cell rescue followed
by CSI otherwise. Five-year OS was 93%. The current ACNS
1,123 for non-germinomas explores the feasibility of reducing
the field to WVI. The overall prognosis for patients with
recurrent germinomas remains excellent. Non-germinomatous
GCT that recur may be salvaged, although the long-term
outcome is worse.
As all Japanese patients benefit from histological
documentation, a three-category strategy is used (103).
Pure germinomas reached 2-year OS of 97% when treated
with three courses of etoposide and carboplatin concomitant
with WVI of 24Gy. The intermediate group (HCG-secreting
germinomas and mixed tumors composed of germinomas
and immature teratomas) received similar treatment, with
an increased dose to the ventricles (30Gy) and a local boost
(20Gy); their 10-year OS was 89%. The high-risk group
(non germinomatous tumors) received three courses of
platinum–etoposide–ifosfamide concomitant with whole-brain
irradiation (30Gy) with a local boost (30Gy) and spinal
(24Gy) radiotherapy; their 10-year OS was 58%. In the ongoing
study, strategy for the intermediate group includes similar
chemotherapy with a decreased dose to the ventricles (23.4Gy)
and an increased boost to the tumor bed (27Gy). The high-risk
group receive a 30.6Gy CSI plus 30.6Gy additional boost
to the tumor with concomitant and maintenance courses
of platinum–etoposide–ifosfamide.
Biology of intracranial (non-)germinomas is lagging behind
due to the lack of availability of tumor tissue in most chemo-
naive patients. Intracranial and extracranial tumors have similar
mutations in KIT (26%), KRAS (15%), NRAS (5%; exclusive from
KIT), mTor (8%), CBL (11%), with copy gain of AKT1 (19%).
Potentially effective drugs in the future include sunitinib and
mTOR inhibitors. Embryonal carcinoma is CD30-positive and
could benefit from brentuximab vedotin.
Liquid biopsy, especially of the CSF, is an attractive surrogate
for tissue sampling; miRNAs are potential candidates for the
follow-up of tumor-mass response to therapy (104).
SPINAL CORD TUMORS
Primary tumors of the spinal cord are uncommon neoplasms
representing 2–4% of all primary tumors of the CNS in adults
(105). The overall incidence of malignant and non-malignant
tumors was 0.97 per 100,000, with only 30% of all spinal cord
tumors being malignant. These tumors can be divided into
extradural and intradural lesions. Extradural tumors account for
almost 60% of spinal cord neoplasms and in most cases are
primarily metastatic in origin; in particular, they derive from
lung, breast, prostate, and lymphoma. Moreover, osteosarcoma,
chondrosarcoma, or multiple myeloma can arise from the
vertebral column.
Intradural tumors can originate in the parenchyma of
the cord (intramedullary lesions) or in the thecal sac but
external to the spinal cord (extramedullary lesions). Symptoms
related to spinal tumors can depend on tumor location and
size, causing back pain, numbness, temperature sensation
disturbance, radiculopathy and other sensorimotor deficits.
Magnetic resonance imaging is the gold standard to assess these
lesions and CT scans can be useful for imaging the osseous spine
and when the primary lesion infiltrates the vertebra.
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Intradural, Extramedullary Tumors
Extramedullary tumors account for more than 70% of intradural
spinal cord neoplasms in adult patients. Most frequent
extramedullary spinal cord tumors include meningiomas
(discussed previously), nerve sheath tumors (schwannomas
and neurofibromas).
Nerve-Sheath Tumors
Nerve-sheath tumors account for 27% of the primitive spinal
cord neoplasms. Almost all are non-malignant neoplasms (98%)
with a male-female rate ratio of 1.11 (105).
Schwannomas are slow-growing lesions that arise from the
dorsal nerve root in most cases. The average age of onset
is 40–60 years and these lesions are almost never malignant.
Usually, schwannomas present as solitary tumors and multiple
spinal schwannomas are often encountered in patients with
neurofibromatosis type 2 (NF2) (106). Surgery is recommended
in case of symptomatic or growing tumors and GTR can be
reached in most cases. Radiotherapy should be used with caution
and only when absolutely necessary, especially in hereditary
diseases; indeed, in these patients the use of radiation therapy
could increase the risk of a malignant tumor in the radiation
field (107) Bevacizumab, an antiangiogenic drug, could also be
beneficial in spinal cord lesions due to its promising activity
in neurofibromatosis type 2-associated vestibular schwannomas
(108); moreover, lapatinib and nilotinib in combination with
radiotherapy demonstrated some benefit in a preclinical model
of NF2 associated peripheral schwannoma (109).
Neurofibromas have characteristics similar to schwannomas
and are classified as general or plexiform histology. Multiple
neurofibromas can be associated with neurofibromatosis type
I (NF-1) and, a small rate of patients can develop malignant
peripheral nerve sheath tumors (MPNST) with dismal clinical
outcome; the cumulative lifetime risk of developing MPNST
in patients with NF1 is about 8–13% (110). The cornerstone
of MPNST treatment remains surgical resection, but is often
not possible due to expected damage to adjacent structures.
However, the important role of surgery was confirmed in a
recent experience of the French Sarcoma Group analyzing 353
patients withMPNST (111). Although, in this retrospective study
tumors were located in the trunk in only 37% of cases overall,
the authors showed a statistically significant impact of radical
surgery in prolonging disease free survival (DFS) and overall
survival (OS). Radiation therapy could be administered to large,
high-grade MPNST whereas, there is no consensus on the use
of chemotherapy for MPNST (112). Recently, a prospective trial
evaluating selumetinib, an oral selective inhibitor of MEK 1 and
2 showed an interesting activity against plexiform neurofibromas
with a partial response of 71% and a disease control rate of
100% (113).
Intradural, Intramedullary Tumors
In adult patients, the most frequent intramedullary tumors are
gliomas. The incidence of spinal cord gliomas has been reported
to be 0.12 per 100,000. Among gliomas, astrocytomas, and
ependymomas (as discussed previously) account for 60–80% of
all spinal gliomas and the incidence has been increasing over the
last 30 years (114).
Diffuse Gliomas
Astrocytomas account for 30–40% of all intramedullary spinal
cord tumors in adults. The average age of onset is the third
decade of life and they are predominantly located in the cervical
region. About 90% of intramedullary astrocytomas are low-grade
and glioblastomas rarely occur (about 1% of all astrocytomas).
GTR is the gold standard treatment for pilocytic astrocytoma
as these tumors are well-circumscribed. Diffuse and high-grade
astrocytomas have an infiltrative pattern and GTR is rarely
completed. In a systematic review, Hamilton et al. showed that
GTR could improve OS both in low and high-grade gliomas while
adjuvant radiotherapy only in high-grade lesions (114, 115).
Chemotherapy could be used for relapse following radiotherapy.
In a retrospective study, temozolomide showed interesting
activity for recurrent low-grade spinal cord astrocytomas after
surgery and radiotherapy: disease control rate was 73% and
median progression free survival (PFS) was 14.5 months (116).
In another retrospective study, bevacizumab reported partial
response in 83% of cases and median OS of 22.8 months in
recurrent high-grade astrocytomas (117).
Of note, spinal cord high-grade astrocytomas could be treated
with targeted therapies; indeed, BRAF alteration status was
demonstrated to be present in about 80% of low-grade spinal
cord astrocytomas and these cases could be considered for a
therapeutic approach with BRAF-MEK inhibitors. Moreover, the
H3F3A K27M mutation, that could be a potential target of
histone deacetylase or demethylase inhibitors, was reported in all
cases of high-grade gliomas (118).
RARE PITUITARY TUMORS
Important changes in the classification of non-neuroendocrine
tumors have been performed in the 4th Edition of the WHO
Classification of Pituitary Tumors (118). Non-neuroendocrine
tumors are less frequent than pituitary adenomas, however
it is important to achieve a differential diagnosis with
other sellar masses (particularly those tumors arising in the
posterior pituitary).
Tumors of the Posterior Pituitary
Tumors arising in the posterior pituitary include the
pituicytomas, the spindle cell oncocytomas, the rare
sellar ependymomas and the granular cell tumors of the
neurohypophysis (1, 118). According to the German Pituitary
Tumor Register, pituicytomas account <0.1% of all sellar tumors
(119). These tumors can be diagnosed as non-functioning
pituitary adenomas due to their similar radiographic and
clinical features.
About the clinical presentation of these tumors is mainly
related to symptoms related to tumor size and compression.
Thus, symptoms resulting from these tumors include: headaches,
visual deficit, hyperprolactinemia, fatigue, and amenorrhea.
These tumors had specific histological features. Nonetheless,
Granular cell tumors and spindle cell oncocytomas shared
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the expression of thyroid transcription factor 1 (TTF-1).
The immunohistochemical detected TTF-1 expression can be
also observed in the specialized glia of the neurohypophysis,
pituitary stalk and pituicytes. Moreover, tumor architecture
and morphology is similar to normal pituicytes suggesting
a shared pituicyte-lineage. All these data suggest that non-
neuroendocrine pituitary tumors may originate from specific
variants of pituicytes. Thus, it would be possible that granular
cell tumors originate from granular variant, pituicytomas from
the light/major variant and spindle cell oncocytomas from the
oncocytic variant (118).
Neuronal and Paraneuronal Tumors
Neuronal and neuroepithelial tumors may rarely arise in
the pituitary and include gangliocytomas, neurocytomas,
neuroblastomas, and paragangliomas. These tumor entities do
not differ from those arising in other locations of the CNS.
Briefly, we describe gangliocytoma and neurocytoma of the sellar
region (1).
Gangliocytoma is a well-differentiated tumor, which is
associated to a slow growth. These tumors had microscopic
features similar to normal hypothalamic neurons (120, 121).
When a glial component can be detected these tumors are called
‘’gangliogliomas” (1). These tumors are generally associated to
adenohypophysial pathology such as: acromegaly with impaired
production of growth hormone-releasing hormone (GHRH),
Cushing disease, precocious puberty and hyperprolactinemia
(120, 121).
Microscopically, these tumors showed large mature ganglion
cells with different size and shape. Abundant cytoplasm
containing Nissl substance can also be found while cells can
be binucleated or multinucleated. Patterns of stain include:
synaptophysin, NeuN, MAP2, S100, and neurofilaments that
highlight the axons and dendrites (122, 123). The glial elements
can be identified with GFAP. Of note, Ki-67/MIB-1 is usually very
low like mitotic rate.
Neurocytoma is a tumor composed of small neurons.
Generally, this is a low-grade tumor with infrequent mitoses
and Ki-67 proliferation index low than 2%. However, ‘’atypical”
neurocytoma can show higher mitotic rate (3 or more mitoses
per 10 high power fields), Ki-67 expression (>3%), necrosis
and microvascular proliferation. These tumors are associated
to worse prognosis (1, 124, 125). Microscopically, these tumors
are characterized by nuclei that range from round to oval with
multiple nucleoli and finely granular chromatin. Cells are round
with small—medium size converging in monotonous sheets and
nests or rosette-like pattern within a vascular fibrillary neuropil.
The cytoplasm is weakly eosinophilic. Occasional acidophilic
hyaline globules within the neuropil resemble Herring
bodies of the posterior pituitary. The immunohistochemical
pattern reveals NeuN and TTF1 positivity in the nuclei
and synaptophysin, chromogranin-A and neurofilaments in
cytoplasm (126–128). Occasionally, S100 protein, calretinin and
CD99 can be observed. Tumors associated to acromegaly and
SIAD could also be express. Adenohypophyseal neuroendocrine
tumors, olfactory neuroblastoma, and paraganglioma, represent
differential diagnosis.
Craniopharyngioma
Several cyst-like lesions may involve the pituitary gland
and include both neoplastic and developmental lesions
(1, 118). Clinically, they may present with signs and
symptoms of a mass lesion impinging on the optic
pathways and/or the hypothalamus. These cystic lesions
and tumors include craniopharyngiomas, Rathke cleft
cysts, epidermoid, and dermoid cysts, and arachnoid cysts
(118). The 2016 WHO classification (1, 118) identifies two
variants of craniopharyngioma, the adamantinomatous and
papillary craniopharyngioma. It has been suggested that
two different subtypes of tumors exists. This hypothesis has
been suggested after the demonstration of distinct genetic
mutations pathways of craniopharyngiomas. CTNNB1
gene mutations (encoding β-catenin protein) is exhibit by
adamantinomatous craniopharyngiomas. This mutation
results in aberrant nuclear accumulation of β-catenin, an
immunohistochemically reliable tool for confirmation of the
diagnosis. On the other hand, mutations of BRAF gene (BRAF
V600E) are the main oncogenic alteration seen in papillary
craniopharyngiomas; similarly, this mutation can be detected
using BRAFV600E immunohistochemistry.
Recently several case reports showed dramatic tumor
responses to BRAF-inhibitors alone or in association with
MEK inhibitors.
Germ Cell Tumors
The sellar/suprasellar region is the second most common site
involved with germ cell tumors in the CNS with involvement
of the hypothalamus, periventricular areas of the third ventricle,
pituitary stalk and pituitary gland (118). Germ cell tumors of
the CNS are histologically identical to the gonadal and extra-
gonadal counterparts and may be divided pathologically into two
major patterns: germinoma and non-germinomatous germ cell
tumors. Germinomas are by far the most common involving this
area. The differential diagnosis of germinomas in the sellar region
includes inflammatory lesions and hematolymphoid tumors.
Tumors of the Bone, Soft Tissues, and
Peripheral Nerves
Lastly, tumors of the bone, soft tissues, and peripheral nerves
may arise in the sella turcica area including chordoma
and chondrosarcoma, meningiomas, solitary fibrous
tumor/hemangiopericytoma, schwannomas, and other rare
peripheral nerve sheath tumors. Briefly, we describe skull
base chordoma.
Chordomas of the Skull Base
Chordomas are malignancies of bone, which originate from
ectopic residuals of the notochord. (129). These are rare tumors
with an estimated incidence of 0.08 per 100,000 patients. Except
for rare tumors originating from extranotochordal sites, the
majority of these tumors take place in the sacrococcygeal region
(50%), spheno-occipital region (35%) and vertebrae (15%) (129–
131). These tumors arise more frequently in males with a peak of
incidence in fifth and sixth decades (129). Chordomas are rare in
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adults below the age of 40 years old and exceptional in children
and adolescents (<5%) (132, 133).
According to theWHOClassification of Soft Tissues and Bone
chordomas can be divided in three subtypes: (i) conventional, (ii)
chondroid, and (iii) dedifferentiated.
The morphology differs for each subtype. Conventional
type is characterized for the presence of “physaliphorous
cells” associated to myxoid matrix while biphasic tumors with
irregular and high-grade undifferentiated sarcoma cells can be
detected in dedifferentiated type. Matrix similar to the hyaline
cartilage can be detected in chondroid type (116, 133, 134).
The ‘’poorly differentiated chordoma” is an entity characterized
by the absence of SMARCB1 (i.e., INI1) expression originated
from the skull base and cervical spine. This subtype has been
described in pediatric patients and has been associated to poor
clinical outcomes (134, 135). Differentiation between chordoma
and chondrosarcoma is possible through the expression of a
wide-spectrum of keratin in immunohistochemistry as well as
expression of T brachyury in chordoma. Moreover, chordomas
express cytokeratin, EMA, s1000 and presents physaliferous
elements, which may help diagnosis.
About prognosis, dedifferentiated chordoma presents worse
PFS and OS compared to classic subtype (136, 137). Indeed,
3-year PFS range from 40% in dedifferentiate chordoma to
85.6% in classic subtype and 100% in chondroid chordoma
(136, 137). Similarly 3 years OS is 60% in dedifferentiated
chordoma, 89.4% in chondroid chordoma and 100% in classic
subtype (136, 137).
Management of chordoma of the skull base is difficult
due to the proximity of these tumors to brain stem and
major arteries (131, 136, 137). Available data seems to support
the role of radical surgery followed by radiation therapy
(especially when excision is incomplete) as best treatment
approach (129, 135, 136). Few and not conclusive data
about efficacy of systemic treatment in chordoma management
are available. Kinases inhibitors have shown only modest
benefit in pilot and phase II studies (129, 130, 135–138)
thus shared opinion is that chemotherapy is not effective in
these tumors.
Some trials are currently evaluating clinical efficacy of
an EZH2 inhibitor named Tazemetostat in patients with
poorly differentiated chordoma with SMARCB1 loss (NCI#
NCT02601950 and NCT02601937) (138). However, due to
the small number of patients enrolled and the short follow
up available preliminary results and reports of efficacy are
limited (138).
CONCLUSION
Rare primary brain tumors in adults form a very large
group of heterogeneous entities. Significant advances have been
accomplished in diagnostic criteria thanks to the 2016 World
Health Organization criteria and the unofficial, but broadly
recognized amendments of the c-IMPACT-NOW Consortium.
Standards of care are lacking for most rare adult primary
brain tumors due to their scarcity. Thus, conducting robust
clinical trials is very challenging. Joining forces in the setting
of EURACAN Domain 10 and other neuro-oncology research
networks will undoubtedly support, on the one hand, routine
medical management of patients and, on the other hand, basic
and clinical research toward improvement of prognosis for
these patients.
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